Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials permanently closed: MA17R and MA20

MA17R and MA20 trials were permanently closed on Wednesday April 19th.

MA17R: A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)

MA20: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer

The permanent closure/termination of these trials will be communicated to sites, participating cooperative groups as well as any pharmaceutical sponsors tomorrow morning.

If you have questions please contact: Christine Bertrim, cbertrim@ctg.queensu.ca